Published in J Antimicrob Chemother on January 01, 1985
Once-daily aminoglycoside therapy. Antimicrob Agents Chemother (1991) 2.31
Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ (1996) 2.29
Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother (1994) 2.28
Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother (1992) 2.18
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother (2004) 2.10
Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers. Antimicrob Agents Chemother (1990) 1.37
Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model. Antimicrob Agents Chemother (1993) 1.25
Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob Agents Chemother (1996) 1.16
Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients. Antimicrob Agents Chemother (1987) 1.12
Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrob Agents Chemother (1995) 1.11
Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob Agents Chemother (1999) 1.11
Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics. Antimicrob Agents Chemother (1998) 1.02
Comparative pharmacokinetics of two multiple-dose mezlocillin regimens in normal volunteers. Antimicrob Agents Chemother (1986) 1.00
Characterization of bactericidal activity of clindamycin against Bacteroides fragilis via kill curve methods. Antimicrob Agents Chemother (1996) 0.87
Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care (2012) 0.85
Clinical pharmacokinetics of cefamandole and ceftazidime administered by continuous intravenous infusion. Antimicrob Agents Chemother (2003) 0.78
Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory. Clin Microbiol Rev (2016) 0.75
Pharmacokinetics and clinical use of cephalosporin antibiotics. J Pharm Sci (1975) 4.01
Penetration of amoxicillin, cefaclor, erythromycin-sulfisoxazole, and trimethoprim-sulfamethoxazole into the middle ear fluid of patients with chronic serous otitis media. J Infect Dis (1982) 3.96
Clinical, epidemiologic and bacteriologic observations of an outbreak of methicillin-resistant Staphylococcus aureus at a large community hospital. Am J Med (1976) 3.86
Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother (1997) 3.17
Activity of minocycline against Acinetobacter calcoaceticus var. anitratus (syn. Herellea vaginicola) and Serratia marcescens. Antimicrob Agents Chemother (1975) 2.92
Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother (1995) 2.49
Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother (1999) 2.06
Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis (2001) 1.72
Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother (1996) 1.68
Overwhelming sepsis associated with group A beta hemolytic streptococci. J Bone Joint Surg Am (1971) 1.66
Gram-negative bacillary meningitis. Am J Med (1975) 1.64
Development of meningitis during cephalothin therapy. Ann Intern Med (1973) 1.62
Pharmacokinetics and pharmacodynamics of total and unbound cefoxitin and cefotetan in healthy volunteers. J Antimicrob Chemother (1989) 1.55
In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci. Diagn Microbiol Infect Dis (1995) 1.48
The penetration characteristics of cefazolin, cephalothin, and cephradine into bone in patients undergoing total hip replacement. J Bone Joint Surg Am (1977) 1.45
Absorption of vancomycin. Ann Intern Med (1984) 1.40
Regulation of VanA- and VanB-type glycopeptide resistance in enterococci. Antimicrob Agents Chemother (2001) 1.38
A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions. J Pharm Sci (1986) 1.34
The association of bacteremic Haemophilus influenzae pneumonia in adults with typable strains. Am J Med (1971) 1.34
Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations. Antimicrob Agents Chemother (2000) 1.33
Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers. Antimicrob Agents Chemother (1991) 1.33
Defective regulation of chemotaxis in cirrhosis. J Lab Clin Med (1975) 1.32
Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa. J Pharmacokinet Biopharm (1988) 1.32
Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother (1997) 1.26
A common source outbreak of Acinetobacter pulmonary infections traced to Wright respirometers. Postgrad Med J (1980) 1.25
Trimethoprim-sulfamethoxazole for bacterial meningitis. Ann Intern Med (1984) 1.25
Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model. Antimicrob Agents Chemother (1993) 1.25
Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae. Antimicrob Agents Chemother (2001) 1.25
Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. Int J Antimicrob Agents (1999) 1.24
Clinical experience on the detection of endotoxemia with the limulus test. J Infect Dis (1973) 1.24
Effect of protein binding on drug penetration into blister fluid. Antimicrob Agents Chemother (1988) 1.22
Flavobacterium meningosepticum meningitis in a newborn infant. Treatment with intraventricular erythromycin. J Pediatr (1974) 1.22
Synergism of cefazolin-gentamicin against enterococci. Antimicrob Agents Chemother (1976) 1.21
Aminoglycoside antibiotics moderately impair granulocyte function. Antimicrob Agents Chemother (1978) 1.20
The pharmacodynamics of aminoglycosides. Clin Infect Dis (1998) 1.18
Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob Agents Chemother (1996) 1.16
Bacteremic Pseudomonas pneumonia. JAMA (1974) 1.15
Integration of pharmacokinetics and pharmacodynamics of methicillin in curative treatment of experimental endocarditis. J Antimicrob Chemother (1984) 1.15
Comparison of concentrations of amoxicillin and ampicillin in serum and middle ear fluid of children with chronic otitis media. J Infect Dis (1977) 1.14
First and second generation cephalosporins. Med Clin North Am (1982) 1.14
Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents (2001) 1.13
Reduction of bacterial titers by low-dose aspirin in experimental aortic valve endocarditis. Infect Immun (1993) 1.11
Magnesium sulfate in eclampsia and pre-eclampsia: pharmacokinetic principles. Clin Pharmacokinet (2000) 1.10
Mechanisms of glycopeptide resistance in enterococci. J Infect (1996) 1.10
Effect of protein binding on the penetration of nonmetabolized cephalosporins into atrial appendage and pericardial fluids in open-heart surgical patients. Antimicrob Agents Chemother (1980) 1.07
Prophylactic antibiotics in cholecystectomy. Lancet (1978) 1.07
Review of cefonicid, a long-acting cephalosporin. Clin Pharm (1984) 1.04
Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1994) 1.04
Further observations on the antimicrobial effects of local anesthetic agents. Curr Ther Res Clin Exp (1975) 1.03
Once-daily aminoglycosides. Conn Med (1992) 1.02
Flavobacterium meningosepticum meningitis: report of selected aspects. Antimicrob Agents Chemother (1978) 1.01
Physiologically based pharmacokinetic model for beta-lactam antibiotics I: Tissue distribution and elimination in rats. J Pharm Sci (1983) 1.01
Meningovascular syphilis after 'appropriate' treatment of primary syphilis. Arch Intern Med (1982) 1.01
Cellulitis due to Streptococcus pneumoniae: case report and review. Clin Infect Dis (1992) 1.01
Treatment of nocardial infection with trimethoprim and sulfamethoxazole. Am J Med (1974) 1.00
Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. Arch Intern Med (1986) 1.00
Treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus with minocycline. J Infect Dis (1990) 0.99
Mycoplasma pneumoniae meningoencephalitis and transverse myelitis in association with low cerebrospinal fluid glucose. Pediatrics (1976) 0.99
Pharmacokinetics and penetration characteristics of cefazolin into human spinal fluid. Curr Ther Res Clin Exp (1976) 0.99
Penetration of cephapirin and cephalothin into the right atrial appendage and pericardial fluid of patients undergoing open-heart surgery. J Infect Dis (1979) 0.98
Effect of saturable serum protein binding on the pharmacokinetics of unbound cefonicid in humans. Antimicrob Agents Chemother (1986) 0.98
Clinical pharmacokinetics of newer cephalosporins. Clin Pharmacokinet (1995) 0.98
Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinet (1989) 0.97
Endocarditis from Serratia marcescens. JAMA (1969) 0.97
Treatment and prevention of oropharyngeal candidiasis. Am J Med (1984) 0.97
Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. Antimicrob Agents Chemother (2001) 0.97
Rapid sensitive fluorometric analysis of cephalosporin antibiotics. J Pharm Sci (1977) 0.97
Intrapulmonary concentrations of telithromycin: clinical implications for respiratory tract infections due to Streptococcus pneumoniae. Chemotherapy (2005) 0.97
Pharmacokinetics of single- and multiple-dose teicoplanin in healthy volunteers. Antimicrob Agents Chemother (1989) 0.96